GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).
GlycoMimetics, Inc.（纳斯达克股票代码：GLYC）是一家处于临床后期阶段的生物技术公司，正在发现和开发基于糖生物学的癌症和炎症性疾病疗法。该公司今天宣布，它将在美国东部时间2024年6月4日星期二上午 8:30 举办一次重要的意见领袖活动，全面概述该公司对复发/难治性（R/R）的Uproleselan的关键性3期研究的数据髓系白血病（AML）。
The event will feature the study's principal investigator Daniel DeAngelo, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and Chief of the Division of Leukemia, Dana-Farber Cancer Institute, who will discuss results from the pivotal Phase 3 study of uproleselan, along with the current AML treatment landscape and unmet patient need.
该研究的首席研究员丹尼尔·迪安杰洛（Daniel DeAngelo），医学博士，哈佛医学院医学教授和达纳-法伯癌症研究所白血病科主任，他们将讨论uproleselan的关键3期研究的结果，以及当前的急性髓细胞白血病治疗格局和未满足的患者需求。
To access the event by phone, please go to this registration link to obtain the dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
要通过电话访问活动，请访问此注册链接以获取拨号的详细信息。鼓励参与者在预定开始时间前 15 分钟进行连接。
A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.
电话会议的网络直播将在GlycoMimetics网站的 “投资者” 选项卡上播出。电话会议结束后的30天内将提供网络直播重播。